Polar Asset Management Partners’s Celldex Therapeutics CLDX Stock Holding History

Polar Asset Management Partners’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-27,389	Closed	-$497K	–	624
2025 Q1	$497K	Sell	27,389 -110,161	-80%	-$2.46M	0.01%	335
2024 Q4	$3.48M	Buy	137,550 +127,850	+1,318%	+$3.47M	0.04%	274
2024 Q3	$330K	Sell	9,700 -1,900	-16%	-$72.4K	0.01%	475
2024 Q2	$429K	Buy	11,600 +1,800	+18%	+$67.9K	0.01%	434
2024 Q1	$411K	Sell	9,800 -84,500	-90%	-$3.47M	0.01%	474
2023 Q4	$3.74M	Sell	94,300 -38,100	-29%	-$1.12M	0.06%	264
2023 Q3	$3.64M	Buy	+132,400	New	+$4.15M	0.08%	284
2022 Q3	–	Sell	-98,600	Closed	-$2.66M	–	1410
2022 Q2	$2.66M	Buy	98,600 +29,400	+42%	+$854K	0.03%	647
2022 Q1	$2.36M	Buy	+69,200	New	+$2.21M	0.03%	603

Other funds holding CLDX

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Polar Asset Management Partners's CLDX Position: Q2 2025 in Review

Polar Asset Management Partners sold out of Celldex Therapeutics (CLDX) in Q2 2025, closing a stake of 27,389 shares — an estimated $497K sold.

Polar Asset Management Partners first reported a position in CLDX in Q1 2022 and held it in 9 quarters. The position peaked at $3.74M in Q4 2023. 180 funds tracked by Wall St. Rank hold CLDX as of Q2 2025.

Polar Asset Management Partners reported no remaining Celldex Therapeutics position as of Q2 2025 after selling out during the quarter.
Polar Asset Management Partners sold 27,389 Celldex Therapeutics shares in Q2 2025, an estimated $497K.
Polar Asset Management Partners first reported a position in Celldex Therapeutics in Q1 2022 and held it in 9 quarters.
Polar Asset Management Partners's Celldex Therapeutics position peaked at $3.74M in Q4 2023.
180 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2025.

Based on Polar Asset Management Partners's 13F filing for Q2 2025, filed 14 Aug 2025.